Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study
Joseph Fokam,Yagai Bouba,Rogers Awoh Ajeh,Dominik Tameza Guebiapsi,Suzane Essamba,Albert Franck Zeh Meka,Ebiama Lifanda,Rose Armelle Ada,Liman Yakouba,Nancy Barbara Mbengono,Audrey Raissa Dzaddi Djomo,Suzie Ndiang Tetang,Samuel Martin Sosso,Jocelyne Carmen Babodo,Olivia Francette Ndomo Ambomo,Edith Michele Temgoua,Caroline Medouane,Sabine Ndejo Atsinkou,Justin Leonel Mvogo,Roger Martin Onana,Jean de Dieu Anoubissi,Alice Ketchaji,Alex Durand Nka,Davy-Hyacinthe Anguechia Gouissi,Aude Christelle Ka'e,Nadine Nguendjoung Fainguem,Rachel Simo Kamgaing,Désiré Takou,Michel Carlos Tommo Tchouaket,Ezechiel Ngoufack Jagni Semengue,Marie Amougou Atsama,Julius Nwobegahay,Comfort Vuchas,Anna Nya Nsimen,Bertrand Eyoum Bille,Sandra Kenmegne Gatchuessi,Francis Ndongo Ateba,Daniel Kesseng,Serge Clotaire Billong,Daniele Armenia,Maria Mercedes Santoro,Francesca Ceccherini-Silberstein,Paul Ndombo Koki,Hadja Cherif Hamsatou,Vittorio Colizzi,Alexis Ndjolo,Carlo-Federico Perno,Anne-Cecile Zoung-Kanyi Bissek
DOI: https://doi.org/10.3390/biomedicines12092083
IF: 4.757
2024-09-12
Biomedicines
Abstract:Mortality in children accounts for 15% of all AIDS-related deaths globally, with a higher burden among Cameroonian children (25%), likely driven by poor virological response. We sought to evaluate viral suppression (VS) and its determinants in a nationally representative paediatric and young adult population receiving antiretroviral therapy (ART). A cross-sectional and multicentric study was conducted among Cameroonian children (<10 years), adolescents (10-19 years) and young adults (20-24 years). Data were collected from the databases of nine reference laboratories from December 2023 to March 2024. A conditional backward stepwise regression model was built to assess the predictors of VS, defined as a viral load (VL) <1000 HIV-RNA copies/mL. Overall, 7558 individuals (females: 73.2%) were analysed. Regarding the ART regimen, 17% of children, 80% of adolescents and 83% of young adults transitioned to dolutegravir (DTG)-based regimens. Overall VS was 82.3%, with 67.3% (<10 years), 80.5% (10-19 years) and 86.5% (20-24 years), and p < 0.001. VS was 85.1% on a DTG-based regimen versus 80.0% on efavirenz/nevirapine and 65.6% on lopinavir/ritonavir or atazanavir/ritonavir. VS was higher in females versus males (85.8% versus 78.2%, p < 0.001). The VS rate remained stable around 85% at 12 and 24 months but dropped to about 80% at 36 months after ART initiation, p < 0.009. Independent predictors of non-VS were younger age, longer ART duration (>36 months), backbone drug (non-TDF/3TC) and anchor drug (non-DTG based). In this Cameroonian paediatric population with varying levels of transition to DTG, overall VS remains below the 95% targets. Predictors of non-VS are younger age, non-TDF/3TC- and non-DTG-based regimens. Thus, efforts toward eliminating paediatric AIDS should prioritise the transition to a DTG-based regimen in this new ART era.